Jun 14, 2013 by Max Macaluso1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask)Two fascinating approaches pharmaceutical companies use to discover new drugs.
Jun 10, 2013 by Max MacalusoHot Off the Press: Dynavax Tumbles 30%What caused this biotech to crash this morning?
Jun 4, 2013 by Max MacalusoWhat's Ahead for Rigel Pharmaceuticals After This 18% Plunge?AstraZeneca leaves its partnership with Rigel following lackluster results from Fostamatinib's late-stage trials.
Jun 3, 2013 by Max MacalusoBreakthrough Melanoma Data Drives Pharmas HigherWhy are Merck and Bristol-Myers Squibb up big today?
Jun 1, 2013 by Max MacalusoClinical Trial Disappointment for This Pharmaceutical GiantWhat does this mean for Merck going forward?
Jun 1, 2013 by Max MacalusoWhat Is the Largest Pharmaceutical Company on the Planet?This question is more difficult to answer than you may think.
May 30, 2013 by Max MacalusoAsk a Fool: What Do You Think About AbbVie?AbbVie has generated a lot of buzz in the pharmaceuticals space ever since it spun off from Abbott Labs. What do we think of it here at the Fool?
May 30, 2013 by Max MacalusoAsk a Fool: What's Behind Albany Molecular's Biggest Drop?Albany Molecular beat on earnings and raised guidance. So why did the market react so poorly?
May 30, 2013 by Max MacalusoDoes This Struggling Drugmaker Have an Ace Up Its Sleeve?What drug candidate should Merck investors be watching?
May 28, 2013 by Max MacalusoWhat This Breakthrough Designation Means for Alexion PharmaceuticalsThis biotech's experimental hypophosphatasia drug was granted "breakthrough therapy designation" today.
May 23, 2013 by Max MacalusoUnclear Future for Merck's Insomnia DrugThe FDA advisory committee has discussed Suvorexant; now shareholders need to get ready for the agency's final decision this summer.
May 21, 2013 by Max MacalusoWhat's Behind Medtronic's 5% Pop?Fourth-quarter results impressed investors today.
May 21, 2013 by Max MacalusoRegeneron and Sanofi: An Unstoppable Biotech Duo?More positive clinical trial data released today.
May 20, 2013 by Max MacalusoAbbVie's New Crohn's Disease Drug CandidateGalapagos and AbbVie's experimental Crohn's disease drug GLPG0634 is entering a phase 2 clinical study.
May 20, 2013 by Max MacalusoWill the FDA Approve Merck's Insomnia Drug?The advisory committee meeting is this Wednesday, but investors will have to wait until the summer to discover the Food and Drug Administration's decision.
May 19, 2013 by Max MacalusoIs Keryx Biopharmaceuticals Burning Too Much Cash?What is Keryx's burn rate, and how much cash does it have on hand?
May 18, 2013 by Max MacalusoAbbVie Investors, Watch This Management ChangeWhat strategy will the company's new chief scientific officer pursue?
May 18, 2013 by Max MacalusoThe New Generic-Drug Battle FrontOne generic pharmaceutical company is determined to chance consumer habits.
May 17, 2013 by Max Macaluso3 Most Important Upcoming FDA Decisions of 2013The Food and Drug Administration will decide on drugs developed by Merck, Antares Pharmaceuticals, and GlaxoSmithKline in the coming months.
May 15, 2013 by Max MacalusoSanofi and Regeneron's Latest PartnershipLate-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.
